Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Thymotrinan trifluoroacetate | 00-00-0 | 98.7% | 531.48 g·mol⁻¹ | C18H32F3N7O8 | 25 MG
Thymotrinan TFA is a biologically active fragment of the thymus hormone thymopoietin, provided as the trifluoroacetate (TFA) salt for research use. It modulates immune responses, affecting both humoral and cellular immunity, and is supplied as a purified synthetic peptide for laboratory studies.
- Immunomodulating peptide that affects humoral and cellular responses.
- Supplied as the trifluoroacetate salt for improved stability and handling.
- High purity suitable for in vitro and preclinical research.
- Available in small-scale quantities for peptide research workflows.
- Molecular weight 531.48 g·mol⁻¹; formula C18H32F3N7O8.
Medchemexpress LLC 6bK (TFA) | 1774353-12-6 | MFCD30182289 | 99.4% | 871.94 g/mol | C43H56F3N7O9 | 5 MG
6bK TFA is a potent, selective insulin-degrading enzyme (IDE) inhibitor used in preclinical research to study insulin metabolism and glucose tolerance. It shows an in vitro IC50 of approximately 50 nM and has been reported to increase circulating insulin and improve oral glucose tolerance in high-fat-fed mice.
- Potent IDE inhibition (IC50 ≈ 50 nM).
- Selective activity for insulin-degrading enzyme.
- High purity (≈99.4%).
- Available as solid and DMSO solution in multiple pack sizes.
- Supplied with analytical documents (COA, HPLC, LCMS).
- Recommended storage: solid -20°C; in solvent -80°C (6 months) or -20°C (1 month).
Medchemexpress LLC KRFK TFA | 99.8% | 577.73 (free base) | 5 MG
KRFK TFA is a peptide derived from TSP-1 that activates TGF-β. It promotes TGF-β-mediated signaling and its downstream role, independently of thrombospondin (TSP) receptors like CD47 and CD36. KRFK TFA is used in research for chronic ocular surface inflammatory disorders.
- Activates TGF-β.
- Promotes TGF-β-mediated signaling.
- Acts independently of thrombospondin (TSP) receptors (CD47 and CD36).
- Can be used for chronic ocular surface inflammatory disorders research.
Medchemexpress LLC CPP9 TFA | 99.9% | 1553.37 | 1 MG
CPP9 TFA is a small, amphipathic, cyclic cell penetrating peptide (CPP). CPPs bind directly to the plasma membrane phospholipids and enter mammalian cells via endocytosis, followed by efficient release from the endosome. It can be used for intracellular delivery of therapeutic agents and chemical probes.
- Small, amphipathic, cyclic cell penetrating peptide
- Binds directly to plasma membrane phospholipids
- Enters mammalian cells via endocytosis
- Efficient release from the endosome
- Used for intracellular delivery of therapeutic agents
- Used for intracellular delivery of chemical probes
FUJIFILM Biosciences Trifluoroacetic Acid Solution (for Gradient Elution) | 76-05-1 | MFCD00004169 | 40mL
Trifluoroacetic Acid Solution (for Gradient Elution) | Putity: 25% | MW: 114.022 | 76-05-1 | MFCD00004169 | 40mL
Medchemexpress LLC Veldoreotide TFA | 2126831-23-8 | 99.0% | 1237.33 | 1 MG
Veldoreotide (DG3173) TFA is a somatostatin analogue that binds to and activates somatostatin receptors (SSTR) 2, 4, and 5. It inhibits growth hormone (GH) secretion in adenomas and shows potential as a pain modulating agent. This product is for research use only.
- Binds to and activates SSTR 2, 4, and 5
- Inhibits growth hormone (GH) secretion
- Potential pain modulating agent
- Purity: 98.97%
- Appearance: White to off-white solid
- Soluble in H2O at 25 mg/mL (requires ultrasonic)
Medchemexpress LLC NN1177 (TFA) | 98.7% | 4570.07 (free base) | 25 MG
NN1177 TFA is a long-acting GLP-1/glucagon receptor co-agonist. It induces dose-dependent body weight loss in diet-induced obese mice. This product is for research use only.
- Long-acting GLP-1/glucagon receptor co-agonist
- Induces dose-dependent body weight loss in diet-induced obese mice
- Reduces CYP3A4 mRNA expression and activity in human hepatocytes
- Improves glucose tolerance in diet-induced obese mice
- Reduces liver fat and inflammatory biomarkers in NASH model mice
Medchemexpress LLC L-lysine, L-valyl-L-glutaminyl-L-isoleucyl-L-valyl-L-tyrosyl- (TFA) | 99.45% | 748.91 | 25 MG
PHF6 TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation, mapped to the third microtubule-binding repeat region of the tau protein. Aggregated PHF6 TFA potentiates NLRP3 inflammasome expression and autophagy in human microglial cells.
- Purity: 99.45%
- Molecular weight: 748.91 (free base)
- Chemical formula: C36H60N8O9.xC2HF3O2
- Appearance: Solid
- Color: White to off-white
- Sequence: Val-Gln-Ile-Val-Tyr-Lys
- Solubility in H2O: ≥ 50 mg/mL
- Store sealed and away from moisture
- Powder storage: -80°C for 2 years, -20°C for 1 year
- In-solvent storage: -80°C for 6 months, -20°C for 1 month
Medchemexpress LLC G-Pen-GRGDSPCA TFA | 111844-17-8 | 948.04 | 1 MG
G-Pen-GRGDSPCA TFA is a peptide identified by its CAS number 111844-17-8. It has a molecular weight of 948.04 and its molecular formula is C35H57N13O14S2. This compound is characterized by the IUPAC Condensed sequence H-Gly-Pen(1)-Gly-Arg-Gly-Asp-Ser-Pro-Cys(1)-Ala-OH.
- Peptide with the sequence GXGRGDSPCA
- Molecular formula C35H57N13O14S2
- Bicyclic heptapeptide structure with disulfide bonds
Medchemexpress LLC Peptide R TFA | 98.3% | 900.08 | 5 MG
Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. It exhibits outstanding capacities to remodel the tumor stroma and can be used for solid tumor research, including glioblastoma.
- Synthetic and specific CXCR4 antagonist
- Exhibits outstanding capacities to remodel the tumor stroma
- Can be used for solid tumor research, including glioblastoma
- Molecular weight is 900.08 (free base)
- Appears as a white to off-white solid
- Sequence is Arg-Ala-Cys-Arg-Phe-Phe-Cys with a disulfide bridge at Cys3-Cys7
Medchemexpress LLC Vh4127 TFA | 1034.35 (free base) | 5 MG
VH4127 TFA is a cyclic peptide that targets the low-density lipoprotein receptor (LDLR) with a KD of 18 nM for human LDLR. It specifically binds to the rodent and human epidermal growth factor (EGF) homology domain of LDLR. It is intended for research use only.
- Targets the low density lipoprotein receptor (LDLR)
- High affinity with a KD of 18 nM for human LDLR
- Specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR
- Documentation: data sheet and handling instructions are available
- Formulation: supplied as a solid
- For research use only
Medchemexpress LLC GRGDSP TFA | 98.0% | 701.61 | 25 MG
GRGDSP (TFA) is an integrin inhibitor. This synthetic linear RGD peptide can inhibit the adherence of tumor cells to endothelial cells of blood vessels, thereby limiting metastasis. It is also utilized to modify the surface of cardiovascular implants, such as vascular grafts, to promote endothelialization, and is widely employed in integrin research as a soluble integrin-blocking RGD-based peptide.
- Inhibits adherence of tumor cells to endothelial cells of blood vessels
- Limits metastasis
- Promotes endothelialization for cardiovascular implants
- Used in integrin research
- Functions as a soluble integrin-blocking RGD-based peptide
Medchemexpress LLC M65 TFA | 99.98% | 4823.53 (free base) | 5 MG
M65 TFA is a deleted peptide of maxadilan (61 a.a.), specifically missing residues between positions 24 and 42. It functions as a specific antagonist of the PACAP type 1 receptor, inhibiting ANP secretion, and is utilized in relevant research.
- Deleted peptide of maxadilan (61 a.a.) with a deletion of residues between positions 24 and 42.
- Acts as a specific antagonist of the PACAP type 1 receptor.
- Inhibits ANP secretion.
- Completely blocks cAMP accumulation stimulated by 100 nM of VIP in rat cortical neurons at 1 μM concentration.
- Partially inhibits cAMP accumulation stimulated by 1 nM of maxadilan in rat cortical neurons at 1 μM concentration.
Medchemexpress LLC Cpn-267 tfa | 1279.27 | 1 MG
Cpn-267 tfa is a selective agonist for neuromedin U receptor 1 (NMUR1) with an EC50 of 0.25 nM. This compound has been shown to suppress body weight gain in mice, suggesting its potential use in the study of obesity. It is provided as a solid for research applications.
- Selective NMUR1 agonist.
- Potent activity at nanomolar concentrations.
- Demonstrated suppression of body weight gain in animal models.
- Suitable for obesity research.